MLchartDataset catalogue

Amevive

Term · Oncology and biomedicine · MLC-T-ONC-000442

A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Amevive is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant. Also called alefacept.

Table 1. Record
IdentifierMLC-T-ONC-000442
FieldOncology and biomedicine
Synonymsalefacept
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-000442",
  "term": "Amevive",
  "field": "Oncology and biomedicine",
  "definition": "A drug that is used to treat certain skin conditions and is being studied in the treatment of cutaneous (skin-related) T-cell cancer and T-cell non-Hodgkin lymphoma. Amevive is made by combining part of an antibody with a protein that blocks the growth some types of T cells. It is a type of fusion protein and a type of immunosuppressant. Also called alefacept.",
  "synonyms": [
    "alefacept"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/amevive/"
}

Record 952 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.